TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2012-06-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00245-12PMID 22710121PMCID PMC3421868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.

  2012cited by this paper
• 101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2

  2012cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Telaprevir for retreatment of HCV infection.

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

  2010cited by this paper
• 1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus

  2010influential reference
• Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection

  2009cited by this paper
• 937 SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE DOSES OF MK-3281 IN HEALTHY SUBJECTS

  2009cited by this paper
• In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

  2009influential reference
• Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.

  2009influential reference
• Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors.

  2009influential reference
• 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors

  2008influential reference
• Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.

  2008cited by this paper
• Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout.

  2008cited by this paper
• The way forward in HCV treatment — finding the right path

  2008cited by this paper
• The emerging field of HCV drug resistance.

  2008cited by this paper
• Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

  2007cited by this paper
• Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

  2007influential reference
• Drug–target residence time and its implications for lead optimization

  2007cited by this paper
• Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole.

  2006cited by this paper
• Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action

  2006cited by this paper
• Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site*

  2005cited by this paper
• Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

  2005cited by this paper
• Diagnosis, management, and treatment of hepatitis C

  2004cited by this paper
• Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.

  2004cited by this paper
• Global burden of disease (GBD) for hepatitis C

  2004cited by this paper
• Global Burden of Disease (GBD) for Hepatitis C

  2004cited by this paper
• Genetic diversity and evolution of hepatitis C virus--15 years on.

  2004cited by this paper
• Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus.

  2003cited by this paper
• Twenty years of therapy for HIV-1 infection

  2003cited by this paper
• Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

  2003cited by this paper
• Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase

  2003cited by this paper
• Efficient Replication of Hepatitis C Virus Genotype 1a RNAs in Cell Culture

  2003cited by this paper
• Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication

  2002cited by this paper
• A 10-Year Experience of Liver Transplantation for Hepatitis C: Analysis of Factors Determining Outcome in Over 500 Patients

  2001cited by this paper
• Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations

  2001cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

  1999cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper
• Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity

  1997cited by this paper
• Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus.

  1996cited by this paper
• Prospective assessment of donor blood screening for antibody to hepatitis C virus by first‐ and second‐generation assays as a means of preventing posttransfusion hepatitis

  1996cited by this paper
• American association for the study of liver diseases

  1992cited by this paper
• Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication.

  1992cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper
• American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury

  1960cited by this paper

• Surface Plasmon Resonance as a Tool in Antiviral Drug Discovery Research

  2026cites this paper
• Antibacterial and antibiofilm efficacy of TMC647055 against methicillin-resistant Staphylococcus aureus

  2025cites this paper
• Ruthenium(II)-Catalyzed Macrocyclization via Site-Selective Hydroarylation of Alkynes: Access to Indoline-Braced Metacyclophanes.

  2025cites this paper
• Antiviral activities of plant-derived indole and β-carboline alkaloids against human and avian influenza viruses

  2023influential citation
• Indole: a Versatile and Promising Heterocycle for the Discovery of Novel Antibacterial and Antifungal Agents

  2022cites this paper
• Antiviral therapeutics directed against RNA dependent RNA polymerases from positive-sense viruses.

  2021cites this paper
• Synthesis of Azepino[1,2‐ a ]indole‐10‐amines via [6+1] Annulation of Ynenitriles with Reformatsky Reagent

  2021cites this paper
• Curing Hepatitis C with Direct‐Acting Antiviral Therapy

  2021cites this paper
• Indole alkaloids inhibit zika and chikungunya virus infection in different cell lines

  2021cites this paper
• Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors

  2020cites this paper
• Antiviral Candidates for Treating Hepatitis E Virus Infection

  2019cites this paper
• Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitor

  2019cites this paper
• Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives.

  2019cites this paper
• Targeting HCV polymerase: a structural and dynamic perspective into the mechanism of selective covalent inhibition

  2018cites this paper
• Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure

  2018cites this paper
• Potential Therapeutic Agents for Feline Calicivirus Infection

  2018cites this paper
• NS5B polymerase inhibitors in phase II clinical trials for HCV infection

  2018cites this paper
• HCV Drug Resistance

  2017cites this paper
• Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection

  2017cites this paper
• Prevalence of NS5B Resistance Mutations in Hepatitis C Virus (HCV) Treatment Naive South Africans

  2017cites this paper
• Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

  2017cites this paper
• Macrocycles, the edge of drug‐likeness chemical space or Goldilocks zone?

  2017cites this paper
• Overview of Macrocycles in Clinical Development and Clinically Used

  2017cites this paper
• Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.

  2017cites this paper
• Broad‐spectrum non‐nucleoside inhibitors for caliciviruses

  2017influential citation
• A REVIEW ON ANTI-HCV AGENTS TARGETING ACTIVE SITE AND ALLOSTERIC SITES OF NON-STRUCTURAL PROTEIN 5B [NS5B]

  2016cites this paper
• Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

  2016influential citation
• Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.

  2016cites this paper
• Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055.

  2016influential citation
• Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance

  2015cites this paper
• Draft Molecular modeling study on the drug resistance mechanism of NS 5 B polymerase to TMC 647055

  2015influential citation
• A practical and efficient synthesis of 6-carboalkoxy-13-cycloalkyl-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives

  2014cites this paper
• HCV-targeted antivirals: current status and future challenges.

  2014cites this paper
• Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors

  2014cites this paper
• Current race in the development of DAAs (direct-acting antivirals) against HCV.

  2014cites this paper
• Current race in the development of DAAs (direct-acting antivirals) against HCV.

  2014cites this paper
• Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?

  2014cites this paper
• Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

  2014cites this paper
• Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

  2014cites this paper
• A review on recent developments of indole-containing antiviral agents

  2014cites this paper
• Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

  2014cites this paper
• Hepatitis C virus-specific directly acting antiviral drugs.

  2013cites this paper
• Hepatitis C Virus: From Molecular Virology to Antiviral Therapy

  2013cites this paper
• Hepatitis C virus: standard-of-care treatment.

  2013cites this paper
• Resistance to Direct-Acting Antivirals

  2012cites this paper